Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated ...